California biologics company LakePharma, with operations in Hopkinton and Worcester, has announced it is making versions of purified COVID-19 proteins available to the biotech community for use in antibody and diagnostic development.
The company announced Tuesday in a press release it had created various versions of recombinant COVID-19 spike proteins using rapid CHO manufacturing platforms. These proteins can be used as reagents for antibody and diagnostic development.
Dr. Hua Tu, president and CEO of LakePharma, said the company has been working with partners on COVID-19 responses since January.
The company said it would make these proteins available under “relaxed business terms” although it did not detail those terms.
